Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids
Launched by WENWEN WANG · Jan 28, 2024
Trial Information
Current as of June 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand why some women experience a recurrence of uterine fibroids after treatment and to develop a prediction model that can help identify those at higher risk. Uterine fibroids are non-cancerous growths in the uterus that can cause various symptoms. The goal of the study is to find ways to detect these recurrences early, so that doctors can intervene sooner and provide better care for patients who might be affected.
To participate in this trial, women must be between the ages of 18 and 50 and have been diagnosed with uterine fibroids through imaging tests like ultrasound. They must also be willing to undergo a surgical procedure called myomectomy to remove the fibroids. However, women with severe infections, a history of cancer, incomplete medical records, or who are pregnant cannot participate. If you qualify, you can expect to contribute valuable information that could help future patients dealing with similar issues.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Age:18-50 years
- • 2. Diagnosed with uterine fibroids (by ultrasound or pathology)
- • 3. Accept myomectomy.
- • 4. Complete clinical data.
- Exclusion Criteria:
- • 1. Severe infectious disease
- • 2. Previous history of malignant tumors
- • 3. Incomplete clinical data.
- • 4. Pregnant
About Wenwen Wang
Wenwen Wang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic interventions. With a focus on rigorous study design and ethical standards, Wenwen Wang leads initiatives that encompass a wide range of therapeutic areas. The sponsor prioritizes collaboration with research institutions and healthcare professionals to ensure the integrity and efficacy of clinical trials. Through meticulous planning and execution, Wenwen Wang aims to contribute valuable insights to the scientific community and enhance the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, None Selected, China
Patients applied
Trial Officials
Shixuan Wang, Phd
Study Chair
Huazhong University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported